Precision Medicine Podcast

This episode treats liquid biopsy as an active clinical problem, not just an emerging technology, and stays centered on how precision oncology reaches patients.

Precision medicine is treated less as a breakthrough story than as an access question: who gets tested, who gets counseling, and who reaches the right therapy in time. Karen Cushman opens a new series with Dr.

Liquid biopsy is framed as a blood test that can deliver results in five to seven days, a speed that matters when fast moving cancers leave little room to wait.

AI and precision medicine sit inside the present of cancer care here, not some distant promise. The discussion keeps its footing on practical questions: what multi-cancer early detection can and cannot do, why current blood tests still run into sensitivity and specificity…

Precision Medicine Podcast centers on a guest who has lived with stage four colorectal cancer since March 2018 and has gone through surgery, chemotherapy, immunotherapy, and a clinical trial.

Biomarker testing sits at the center of this episode, and the policy angle stays grounded in that reality. Karen Cushman keeps the discussion practical while Hilary G.

Precision medicine is treated here less like a slogan than like a logistics problem: who gets tested, who gets guided, and how cancer care becomes a little less punishing to navigate.

Precision Medicine Podcast presents colorectal cancer as a lived reality, not an abstract diagnosis. Trevor Maxwell, a stage four survivor, patient advocate, and founder of Man Up to Cancer, describes the diagnosis that changed his life and the mental strain that followed.